Cargando…

The clinical characteristics of patients with primary non‐prostate‐specific membrane antigen‐expressing prostate cancer on preoperative positron emission tomography/computed tomography

Detalles Bibliográficos
Autores principales:	Veerman, Hans, Donswijk, Maarten, Bekers, Elise, olde Heuvel, Judith, Bodar, Yves J.L., Boellaard, Thierry N., van Montfoort, Maurits L., van Moorselaar, R. Jeroen A., Oprea‐Lager, Daniela E., van Leeuwen, Pim J., Vis, André N., van der Poel, Henk G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299595/ https://www.ncbi.nlm.nih.gov/pubmed/34854204 http://dx.doi.org/10.1111/bju.15664

Ejemplares similares

The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography
por: Veerman, Hans, et al.
Publicado: (2022)

Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer
por: Bodar, Yves J.L., et al.
Publicado: (2022)

Predicting early outcomes in patients with intermediate‐ and high‐risk prostate cancer using prostate‐specific membrane antigen positron emission tomography and magnetic resonance imaging
por: Meijer, Dennie, et al.
Publicado: (2021)

Higher Preoperative Maximum Standardised Uptake Values (SUV(max)) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [(68)Ga]Ga-PSMA-11 and [(18)F]DCFPyL Positron Emission Tomography/Computed Tomography
por: de Bie, Katelijne C. C., et al.
Publicado: (2023)

Management impact of (18)F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study
por: Meijer, Dennie, et al.
Publicado: (2021)

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature
por: Luiting, Henk B., et al.
Publicado: (2019)

Comment on Rosenzweig et al. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates. J. Pers. Med. 2022, 12, 410
por: Veerman, Hans, et al.
Publicado: (2022)

Optimization and validation of (18)F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer
por: Luining, Wietske I., et al.
Publicado: (2023)

External Validation of Two Nomograms Developed for (68)Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer (18)F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
por: Luiting, Henk B., et al.
Publicado: (2021)

Distribution of prostate cancer recurrences on gallium‐68 prostate‐specific membrane antigen ((68)Ga‐PSMA) positron‐emission/computed tomography after radical prostatectomy with pathological node‐positive extended lymph node dissection
por: Huits, Thijs H., et al.
Publicado: (2020)

Detection of prostate cancer with (18)F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial
por: Bodar, Y. J. L., et al.
Publicado: (2020)

Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
por: Jansen, B. H. E., et al.
Publicado: (2020)

Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer: Con
por: van der Poel, Henk
Publicado: (2021)

Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020)

Clinical verification of (18)F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer
por: Meijer, Dennie, et al.
Publicado: (2020)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
por: Luining, Wietske I., et al.
Publicado: (2022)

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options
por: Zuur, Lotte G., et al.
Publicado: (2023)

State of the Art in Prostate-specific Membrane Antigen–targeted Surgery—A Systematic Review
por: Berrens, Anne-Claire, et al.
Publicado: (2023)

Dual-Phase PET-CT to Differentiate [(18)F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer
por: Oprea-Lager, Daniela E., et al.
Publicado: (2012)

Abandon the Label of Clinically Insignificant Prostate Cancer
por: Mertens, Laura S., et al.
Publicado: (2022)

(68)Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
por: Wondergem, M., et al.
Publicado: (2019)

Prostate MRI for Improving Personalized Risk Prediction of Incontinence and Surgical Planning: The Role of Membranous Urethral Length Measurements and the Use of 3D Models
por: Boellaard, Thierry N., et al.
Publicado: (2023)

Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer
por: LIU, YIYAN
Publicado: (2014)

Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
por: Oprea-Lager, Daniela E., et al.
Publicado: (2021)

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels
por: Meijer, Dennie, et al.
Publicado: (2019)

Comparison of (68)Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis
por: Ling, Sui Wai, et al.
Publicado: (2021)

Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study
por: Donswijk, Maarten L., et al.
Publicado: (2020)

Making the Case for Prostate-Specific Membrane Antigen-Targeted Positron Emission Tomography/Computed Tomography in Suspected Prostate Cancer
por: Singh, Harmandeep
Publicado: (2020)

Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
por: Asokendaran, Marcus Edward, et al.
Publicado: (2019)

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting
por: Mehra, Niven, et al.
Publicado: (2023)

Diagnosis of prostatitis by 18-F-fluorodeoxyglucose positron emission tomography
por: Ho, Thien Anh, et al.
Publicado: (2009)

Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography
por: Jadvar, Hossein
Publicado: (2015)

Positron emission tomography in prostate cancer: An update on state of the art
por: Das, Chandan Jyoti, et al.
Publicado: (2018)

Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan
por: Agarwal, Krishan Kant, et al.
Publicado: (2016)

Upcoming Role of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Detecting Occult Metastases in Prostate Cancer
por: Gupta, Parul, et al.
Publicado: (2019)

Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography
por: Gupta, Manoj, et al.
Publicado: (2020)

Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Dundee, Philip, et al.
Publicado: (2022)

Occult Prostate Cancer Detected with 18F-Fluorocholine Positron Emission Tomography/Computed Tomography
por: Xie, Wanying, et al.
Publicado: (2014)

Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers
por: Luining, Wietske I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m7m19g5ve331ggpemln5dku2ag